open access

Vol 7, No 4 (2011)
Review paper
Published online: 2011-10-26
Get Citation

Molecular predictive markers in the treatment of colorectal cancer with monoclonal antibodies targeting the epidermal growth factor receptor (EGFR)

Aleksandra Łacko, Marcin Ekiert, Katarzyna Soter
Onkol. Prak. Klin 2011;7(4):224-229.

open access

Vol 7, No 4 (2011)
REVIEW ARTICLES
Published online: 2011-10-26

Abstract

Colorectal cancer is the second common cancer in Poland. Treatment of metastatic disease remains a major problem, with poor overall survival of about 18 to 20 months. In recent years, treatment results of advanced disease substantially improved due to the availability of new and more effective chemotherapeutic and molecular targeted agents. Cetuximab and panitumumab, monoclonal antibodies targeting the epidermal growth factor receptor in the last 5 years have been effectively used in the treatment of metastatic colorectal cancer. As their activity in general population is limited, financial costs and morbidity are substantial, there is a need to optimize patients selection. Molecular markers serve as important tools for predicting benefits from the treatment. Unfortunately, despite extensive research, only KRAS — powerful negative predictive marker has been validated and accepted into routine clinical practice in colorectal cancer patients. Numerous potential biomarkers such as BRAF, NRAS, PTEN, PI3KCA, EGFR polisomy and amplification, EGFR ligands are investigated, and some of the studies show promising results.
Onkol. Prak. Klin. 2011; 7, 4: 224–229

Abstract

Colorectal cancer is the second common cancer in Poland. Treatment of metastatic disease remains a major problem, with poor overall survival of about 18 to 20 months. In recent years, treatment results of advanced disease substantially improved due to the availability of new and more effective chemotherapeutic and molecular targeted agents. Cetuximab and panitumumab, monoclonal antibodies targeting the epidermal growth factor receptor in the last 5 years have been effectively used in the treatment of metastatic colorectal cancer. As their activity in general population is limited, financial costs and morbidity are substantial, there is a need to optimize patients selection. Molecular markers serve as important tools for predicting benefits from the treatment. Unfortunately, despite extensive research, only KRAS — powerful negative predictive marker has been validated and accepted into routine clinical practice in colorectal cancer patients. Numerous potential biomarkers such as BRAF, NRAS, PTEN, PI3KCA, EGFR polisomy and amplification, EGFR ligands are investigated, and some of the studies show promising results.
Onkol. Prak. Klin. 2011; 7, 4: 224–229
Get Citation

Keywords

colorectal cancer; predictive factors; molecular markers

About this article
Title

Molecular predictive markers in the treatment of colorectal cancer with monoclonal antibodies targeting the epidermal growth factor receptor (EGFR)

Journal

Oncology in Clinical Practice

Issue

Vol 7, No 4 (2011)

Article type

Review paper

Pages

224-229

Published online

2011-10-26

Bibliographic record

Onkol. Prak. Klin 2011;7(4):224-229.

Keywords

colorectal cancer
predictive factors
molecular markers

Authors

Aleksandra Łacko
Marcin Ekiert
Katarzyna Soter

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl